STIFEL 2026 HEALTHCARE CONFERENCE - BICARA THERAPEUTICS INC

Explicit Guidance:

• Runway & Funding: Guided to have sufficient cash ($442.3M at quarter end) to fund the Fortify trial through the survival endpoint, the Fortify Flex trial, initial medical affairs, commercial build, and signal-seeking work in other indications (including colorectal cancer) into early 2029.

Business-Segment Outlook:

• Lead Indication (Head & Neck Cancer):
  • Topline Data Timing: Anticipating top-line data for the pivotal Fortify HNL1 trial in recurrent metastatic head and neck cancer in the middle of next year.
  • Interim Analysis Strategy: Committed to conducting an interim analysis for overall survival (OS) within the current trial; timing will be determined by the accrual rate of death events, with a view to potentially aligning it with the response rate interim analysis if event triggers are met sooner.
  • Market Sizing: Projects the recurrent metastatic head and neck cancer market (specifically HPV-negative with CPS >1) to reach $5 billion by 2030 in the U.S.
  • Clinical Endpoints: Expects to demonstrate a "best-in-class" overall survival profile driven by the depth and durability of response, aiming for a statistically significant benefit with a smaller sample size compared to competitors.
• Parallel Development (Fortify Flex):
  • Trial Objective: Aiming to demonstrate that transitioning patients from weekly induction (12 weeks) to every-three-week maintenance does not result in a loss of response (endpoint: proportion of patients remaining in response at 24-week landmark).
  • Timeline: The trial was initiated in the third quarter of the previous year; results expected to inform labeling and dosing strategy.
  • Target Profile: Expects the every-three-week schedule to maintain efficacy while potentially improving the tolerability profile (reducing anemia and mucosal bleeding) by lowering cumulative exposure after tumor debulking.
• Other Indications (Colorectal Cancer):
  • Data Presentation: Efficacy and safety data for the third-line setting will be presented at ASCO GI in January of the upcoming year.
  • Strategic Focus: Primary goal is to assess safety and tolerability to enable progression into earlier lines of therapy (first or second line) in combination with chemotherapy or other agents, rather than seeking registration solely in the third-line setting.
  • Signal Expectations: Targeting activity benchmarks of 10–15% response rates (comparable to pitormab/InSight) as a baseline for viability, with potential for higher efficacy in combination regimens.

Market and Competitive Outlook:

• Competitor Analysis (Genmab/Pedosisymptomab):
  • Interprets recent Phase 3 data as likely consistent with historical Pembro control arms (response rates 19–25% in blended populations), projecting mid-to-low 50s or low 60s in the HPV-negative population.
  • Anticipates the hazard ratio for overall survival may deteriorate over time due to the inclusion of HPV-positive patients and the early nature of the current data analysis.
  • Believes their HPV-negative-only focus offers a differentiation advantage in "apples-to-apples" comparisons.
• Competitor Analysis (J&J/Amivantamab):
  • Critiques the J&J triplet regimen (Pembro + Amivantamab + Chemo) for delayed time-to-response (>9 weeks) and identical PFS to the Pembro + Amivantamab dual arm (~7 months), contrasting this with their own HPV-negative PFS of 9.9 months.
  • Predicts limited commercial uptake for the J&J triplet due to high toxicity (26% discontinuation, >10% Grade 5 events) and lack of rapid debulking compared to their agent.
  • Assesses minimal competitive impact from J&J's accelerated approval in the second-line setting on the Fortify trial, noting that most trial patients are either non-eligible for that indication or have already progressed.
• Market Dynamics:
  • Usage: KOLs anticipate Fisera (Bicara's lead) being utilized in the vast majority of frontline patients upon approval.
  • Durability: Differentiation strategy relies on extending duration of therapy (DOR) and overall survival (OS) tails, contrasting with the declining durability seen when chemotherapy is added to Pembro in the KEYNOTE-48 trial.
  • Response Rates: Anticipates significantly enhancing the responder population (up to 3x current rates) and increasing therapy duration compared to Keytruda alone (currently 5–10% of global Keytruda sales in this population).

Macro / Industry Outlook:

• Regulatory Path: Views the "war" as winning on the final label content (safety, dosing, and eligibility criteria) rather than just top-line statistical significance, acknowledging the high bar for TGF-beta approval.
• Adoption Barriers: Focuses on proving that the molecule can sustain long-term outcomes without the toxicity that previously caused trial attrition in the class.

Strategic Initiatives:

• Clinical Program Acceleration: Prioritizing rapid patient enrollment in Fortify HNL1 and Fortify Flex to accelerate data readouts.
• Label Optimization: Designing the Fortify Flex trial specifically to support a flexible dosing schedule (every 3 weeks) that aligns with Keytruda's dosing intervals (every 3 or 6 weeks) to facilitate commercial adoption.
• Pipeline Expansion: Allocating cash flow to signal-seeking work in colorectal cancer and other indications while commercial infrastructure is built.

Risks and Headwinds to Outlook:

• Competitor Uncertainty: The final regulatory label for Genmab's pidot-symptomab remains uncertain ("jury is still out"), which could impact the competitive landscape.
• Data Timing Risks: While confident in the ability to accrue death events faster than Genmab, the exact timing of the OS interim analysis is variable and dependent on blinded accrual data.
• Toxicity Management: Potential for TGF-beta-specific AEs (anemia, mucosal bleeding) in deep responders, though the team believes a maintenance dosing strategy will mitigate this.
• Market Size Assumptions: The $5 billion market projection by 2030 relies on the successful expansion of the responder population and increased duration of therapy.

Management Tone on the Future:

• High Confidence: Management expresses a "high degree of confidence" in the ability to get the drug approved and highlights the unique biological profile (depth and durability) as a differentiator.
• Strategic Caution: Adopts a "not reckless" approach regarding interim analyses, preferring to wait for sufficient maturity of data rather than releasing premature signals.
• Focus on Label: Emphasizes that long-term commercial success depends on the "label we are able to put in the hands of our sales representatives," indicating a pragmatic, label-driven mindset.

Miscellaneous:

• Operational Details: The Fortify Flex trial randomizes 150 patients after 12 weeks of weekly therapy to test non-inferiority of the every-three-week regimen.
• Geographic Enrollment: Roughly 25–30% of the Fortify trial is U.S.-based, with significant enrollment front-loaded early; a disproportionate amount of current enrollment is now occurring outside the U.S.